Reports

Sale

Irritable Bowel Syndrome Treatment Market

Global Irritable Bowel Syndrome Treatment Market Size: By Type: IBS-C, IBS-D; By Application: Cardiology, Urology and Nephrology, Oncology, Gastroenterology, Others; By End User: Hospitals, Clinics and Research Laboratories, Others; Regional Analysis; Market Dynamics: SWOT Analysis; Supplier Landscape; 2024-2032

Global Irritable Bowel Syndrome Treatment Market Outlook

The global irritable bowel syndrome treatment market size attained a value of about USD 2.63 billion in 2023. The market is anticipated to grow at a CAGR of 10.1% during the forecast period of 2024-2032. The global irritable bowel syndrome treatment market share is anticipated to achieve a value of USD 6.27 billion by 2032.

 

The market is being driven by the increasing prevalence of target diseases and the expanded use of medicines for such diseases. The global market is being dominated by North America.

 

Irritable Bowel Syndrome Treatment Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Properties and Applications

Irritable bowel syndrome is among the most prevalent functional disorders, with an approximate global prevalence of 10-15%. The actual cause of the symptoms is not known, and symptoms may arise from changes in the activity of the brain, nervous system, and the gut. This can affect the regular feeling and function of the bowel.

 

Global Irritable Bowel Syndrome Treatment Market By Application

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Based on type, the industry can be divided into IBS-C and IBS-D.

IBS-C can be further divided into:

  • IBS-C Market
  • Linzess/Constella
  • Amitiza
  • Others

IBS-D is further segmented into:

  • Xifaxan
  • Viberzi
  • Others

The industry can be broadly categorised based on its applications into:

  • Cardiology
  • Urology and Nephrology
  • Oncology
  • Gastroenterology
  • Others

The EMR report looks into the regional markets of irritable bowel syndrome treatment like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

 

Global Irritable Bowel Syndrome Treatment Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Analysis

Improved marketing of existing products in various regions is likely to boost the demand over the forecast period 2024-2032. The increasing Linzess adoption in the USA, Europe, as well as Japan, has contributed greatly to the growth of revenues. In January 2020, Linzess was approved in China, which is expected to improve the demand further.

IBS’ continually rising economic burden impacts the quality of jobs and results in higher healthcare costs. In addition, this increased awareness of the disease has, therefore, encouraged the growth of the global irritable bowel syndrome treatment industry. However, the high prevalence of anxiety and depression is expected to catalyse the growth of the demand for irritable bowel syndrome over the forecast period.

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global irritable bowel syndrome treatment market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Takeda Pharmaceutical Company Limited
  • Astellas Pharma
  • Ironwood Pharmaceuticals, Inc.
  • AstraZeneca
  • Sebela Pharmaceuticals Inc.
  • Bausch Health
  • Salix Pharmaceuticals
  • Abbott Laboratories.
  • Johnson & Johnson Services Inc.
  • GlaxoSmithKline plc
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • LEXICON PHARMACEUTICALS, INC

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Application
  • End User
  • Region
Breakup by Type
  • IBS-C
  • IBS-D
Breakup by Application
  • Cardiology
  • Urology and Nephrology
  • Oncology
  • Gastroenterology
  • Others
Breakup by End User
  • Hospitals
  • Clinics and Research Laboratories
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
  • Industry Events, Initiatives, and Trends
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Takeda Pharmaceutical Company Limited
  • Astellas Pharma
  • Ironwood Pharmaceuticals, Inc.
  • AstraZeneca
  • Sebela Pharmaceuticals Inc.
  • Bausch Health
  • Salix Pharmaceuticals
  • Abbott Laboratories.
  • Johnson & Johnson Services Inc.
  • GlaxoSmithKline plc
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • LEXICON PHARMACEUTICALS, INC
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Irritable Bowel Syndrome Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Irritable Bowel Syndrome Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Irritable Bowel Syndrome Epidemiology (2016-2031)
    5.3    Europe Irritable Bowel Syndrome Epidemiology (2016-2031)
    5.4    Asia-Pacific Irritable Bowel Syndrome Epidemiology (2016-2031)
    5.5    Latin America Irritable Bowel Syndrome Epidemiology (2016-2031)
    5.6    Middle East & Africa Irritable Bowel Syndrome Epidemiology (2016-2031)
6    Global Irritable Bowel Syndrome Treatment Market Overview 
    6.1    Global Irritable Bowel Syndrome Treatment Market Historical Value (2017-2023) 
    6.2    Global Irritable Bowel Syndrome Treatment Market Forecast Value (2024-2032)
7    Global Irritable Bowel Syndrome Treatment Market Landscape
    7.1    Irritable Bowel Syndrome Treatment: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Irritable Bowel Syndrome Treatment: Product Landscape
        7.2.1    Analysis by Product
        7.2.2    Analysis by End User
8    Irritable Bowel Syndrome Treatment Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Irritable Bowel Syndrome Treatment Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Global Irritable Bowel Syndrome Treatment Market Segmentation
    11.1    Global Irritable Bowel Syndrome Treatment Market by Type
        11.1.1    Market Overview
        11.1.2    IBS-C
            11.1.2.1    IBS-C Market
            11.1.2.2    Linzess/Constella
            11.1.2.3    Amitiza
            11.1.2.4    Others
        11.1.3    IBS-D
            11.1.3.1    Xifaxan
            11.1.3.2    Viberz
            11.1.3.3    Others
    11.2    Global Irritable Bowel Syndrome Treatment Market by Application
        11.2.1    Market Overview
        11.2.2    Cardiology
        11.2.3    Urology and Nephrology
        11.2.4    Oncology
        11.2.5    Gastroenterology
        11.2.6    Others
    11.3    Global Irritable Bowel Syndrome Treatment Market by End User
        11.3.1    Market Overview
        11.3.2    Hospitals
        11.3.3    Clinics and Research Laboratories
        11.3.4    Others
    11.4    Global Irritable Bowel Syndrome Treatment Market by Region
        11.4.1    Market Overview
        11.4.2    North America
        11.4.3    Europe 
        11.4.4    Asia Pacific
        11.4.5    Latin America
        11.4.6    Middle East and Africa
12    North America Irritable Bowel Syndrome Treatment Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Irritable Bowel Syndrome Treatment Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Irritable Bowel Syndrome Treatment Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Irritable Bowel Syndrome Treatment Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Irritable Bowel Syndrome Treatment Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Patent Analysis
    18.1    Analysis by Type of Patent
    18.2    Analysis by Publication Year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation 
    18.7    Analysis by Key Players
19    Grants Analysis
    19.1    Analysis by year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Application
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization 
20    Clinical Trials Analysis
    20.1     Analysis by Trial Registration Year
    20.2    Analysis by Trial Status
    20.3    Analysis by Trial Phase
    20.4    Analysis by Therapeutic Area
    20.5    Analysis by Geography
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Partnership and Collaborations Analysis
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    Takeda Pharmaceutical Company Limited
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    Astellas Pharma
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Ironwood Pharmaceuticals, Inc.
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    AstraZeneca
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    Sebela Pharmaceuticals Inc.
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    Bausch Health
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    Salix Pharmaceuticals
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Abbott Laboratories.
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Johnson & Johnson Services Inc.
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    GlaxoSmithKline plc
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
    23.11    Ono Pharmaceutical Co., Ltd.
        23.11.1    Financial Analysis
        23.11.2    Product Portfolio
        23.11.3    Demographic Reach and Achievements
        23.11.4    Mergers and Acquisitions
        23.11.5    Certifications
    23.12    Pfizer Inc.
        23.12.1    Financial Analysis
        23.12.2    Product Portfolio
        23.12.3    Demographic Reach and Achievements
        23.12.4    Mergers and Acquisitions
        23.12.5    Certifications
    23.13    LEXICON PHARMACEUTICALS, INC
        23.13.1    Financial Analysis
        23.13.2    Product Portfolio
        23.13.3    Demographic Reach and Achievements
        23.13.4    Mergers and Acquisitions
        23.13.5    Certifications
24    Irritable Bowel Syndrome Treatment - Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket


*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

In 2023, the global irritable bowel syndrome treatment market attained a value of nearly USD 2.63 billion.

The market is projected to grow at a CAGR of 10.1% between 2024 and 2032.

The market is being driven by the rising prevalence of irritable bowel syndrome owing to changes in brain, nervous system, or the gut.

The market growth in the forecast period can be associated with the rising awareness of irritable bowel syndrome and the corresponding measures undertaken for effective treatment.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The major types of irritable bowel syndrome treatment are IBS-C and IBS-D.

The significant applications of irritable bowel syndrome treatment include cardiology, urology and nephrology, oncology, and gastroenterology, among others.

The major players in the industry are Ironwood Pharmaceuticals, Inc., Allergan, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, AstraZeneca, Sebela Pharmaceuticals Inc., Synergy Pharmaceuticals Inc., Synthetic Biologics, Inc., Bausch Health Companies Inc., and Ardelyx, among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER